RANKL inhibition for giant cell lesions of the jaw: A retrospective cohort analysis-Reference-Cited by-同舟云学术

RANKL inhibition for giant cell lesions of the jaw: A retrospective cohort analysis

Published:2022-11 Issue: Volume:175 Page:263-273
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Schreuder Willem H.,Lipplaa Astrid,Cleven Arjen H.G.,van den Berg Henk,Bisschop Peter H.^ORCID,de Jongh Renate T.^ORCID,Witjes Max J.H.^ORCID,Kessler Peter A.W.H.,Merkx Matthias A.W.^ORCID,Edelenbos Esther,Klop Cornelis,Schreurs Ruud,Westermann Anneke M.,Tromp Jacqueline M.,Levenga Henriette,Gelderblom Hans,de Lange Jan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Incidence and disease-free survival after surgical therapy of central giant cell granulomas of the jaw in The Netherlands: 1990-1995;de Lange;Head Neck,2004

2. Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options;de Lange;Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2007

3. Central giant cell lesions of the jaws. A clinical, radiologic, and histopathologic study;Whitaker;Oral Surg Oral Med Oral Pathol,1993

4. Central giant cell lesions of the jaws: a clinicopathologic study;Chuong;J Oral Maxillofac Surg,1986

5. The surgical treatment of central giant cell granuloma of the mandible;Bataineh;J Oral Maxillofac Surg,2002

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benign Non-Odontogenic Pathology in Children;Oral and Maxillofacial Surgery Clinics of North America;2024-08

2. Study on the Method and Timing of Discontinuation of Denosumab before Operation for Campanacci Stage III Giant Cell Tumor of Bone in Limbs and Joints;Advances in Clinical Medicine;2024

3. Current concepts in targeted therapies for benign tumors of the jaw — A review of the literature;Journal of Cranio-Maxillofacial Surgery;2023-10

4. Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study;The Oncologist;2023-07-14

5. Calcitonin/peginterferon;Reactions Weekly;2022-11-26